SAS® Press announces Analysis of Clinical Trials Using SAS®: A Practical Guide
While there are many useful texts that address the fundamental statistical and scientific principles underlying the design and analysis of clinical trials, researchers have few references available to them that address the problems commonly encountered in real-world clinical trials...
CARY, N.C. (April 2, 2005) - It is estimated that nearly 10,000 clinical studies are conducted every year around the world. While there are many useful texts that address the fundamental statistical and scientific principles underlying the design and analysis of clinical trials, researchers have few references available to them that address the problems commonly encountered in real-world clinical trials. Filled with examples from actual trials and case studies, Analysis of Clinical Trials Using SAS: A Practical Guide bridges that gap, offering SAS solutions that can be implemented quickly and efficiently. Topics reflect the International Conference on Harmonization (ICH) guidelines for the pharmaceutical industry.
Book reviewer Peter Westfall of Texas Tech University commends the methodologies illustrated in the book. "Because clinical trials are so highly regulated, some of the most rigorous and highly respected statistical tools are used in this arena. The methodologies covered in this book have applicability to the design and analysis of experiments well beyond clinical trials; researchers in all fields who carry out comparative studies would do well to have it on their bookshelves."
Clinical statisticians, research scientists, and graduate students in biostatistics will benefit greatly from the decades of clinical research experience compiled in this book, coauthored by industry leaders Alex Dmitrienko, Geert Molenberghs, Christy Chuang-Stein, and Walter Offen, and published by SAS Press.
Analysis of Clinical Trials Using SAS: A Practical Guide
ISBN: 1-59047-504-6 * Pages: 436 * US Price $69.95 (not including tax or S/H) * 1-800-727-3228
About SAS Press:
SAS Press is an imprint of SAS Publishing, a business unit of SAS, the market leader in providing a new generation of business intelligence software and services that create true enterprise intelligence. SAS solutions are used at more than 40,000 sites -- including 96 of the top 100 companies on the FORTUNE Global 500 -- to develop more profitable relationships with customers and suppliers; to enable better, more accurate and informed decisions; and to drive organizations forward. SAS is the only vendor that completely integrates leading data warehousing, analytics and traditional BI applications to create intelligence from massive amounts of data. For nearly three decades, SAS has been giving customers around the world The Power to Know. Visit us at www.sas.com.
SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. indicates USA registration. Other brand and product names are trademarks of their respective companies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
